Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The rationale for mTOR inhibition in epithelial ovarian cancer.
Trinh XB, van Dam PA, Dirix LY, Vermeulen PB, Tjalma WA. Trinh XB, et al. Among authors: tjalma wa. Expert Opin Investig Drugs. 2009 Dec;18(12):1885-91. doi: 10.1517/13543780903321508. Expert Opin Investig Drugs. 2009. PMID: 19888868 Review.
Preoperative ultrasound staging of the axilla make's peroperative examination of the sentinel node redundant in breast cancer: saving tissue, time and money.
Van Berckelaer C, Huizing M, Van Goethem M, Vervaecke A, Papadimitriou K, Verslegers I, Trinh BX, Van Dam P, Altintas S, Van den Wyngaert T, Huyghe I, Siozopoulou V, Tjalma WA. Van Berckelaer C, et al. Among authors: tjalma wa. Eur J Obstet Gynecol Reprod Biol. 2016 Nov;206:164-171. doi: 10.1016/j.ejogrb.2016.09.006. Epub 2016 Sep 20. Eur J Obstet Gynecol Reprod Biol. 2016. PMID: 27697620
Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties.
Van de Wiel M, Dockx Y, Van den Wyngaert T, Stroobants S, Tjalma WAA, Huizing MT. Van de Wiel M, et al. Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:144-156. doi: 10.1016/j.ejogrb.2016.12.014. Epub 2016 Dec 14. Eur J Obstet Gynecol Reprod Biol. 2017. PMID: 28039758 Review.
Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
Tjalma WAA, Van den Mooter T, Mertens T, Bastiaens V, Huizing MT, Papadimitriou K. Tjalma WAA, et al. Eur J Obstet Gynecol Reprod Biol. 2018 Feb;221:46-51. doi: 10.1016/j.ejogrb.2017.12.006. Epub 2017 Dec 7. Eur J Obstet Gynecol Reprod Biol. 2018. PMID: 29245056
219 results